FDA grants Fast Track to Baxter JAK inhibitor

CTI Biopharma has scored a Fast Track designation for its JAK2 inhibitor pacritinib, CTI and its partner Baxter announced. The experimental drug is being reviewed for patients with intermediate or high-risk myelofibrosis. The pursued indication also includes patients with disease or treatment-induced thrombocytopenia, a state in which patients have low platelet levels.

The oral tyrosine kinase inhibitor is being reviewed based on the firm's Phase-III PERSIST trials. The companies said in a statement that pacritinib may have an edge over other JAK inhibitors because it appears to be associated with fewer cases of treatment-stimulated cases of thrombocytopenia.

CTI and Baxter partnered up last year in a worldwide license agreement in which both companies will commercialize the drug in the US, but Baxter will have full commercial rights everywhere else.

You must be a registered member of MMM to post a comment.
 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.